Takeda Pharmaceutical Co Ltd - Q3 FY2020 Summary
Business Context and Reporting Period
This Form 6-K reports Takeda Pharmaceutical Company Limited's Quarterly Securities Report for the nine-month period ended December 31, 2020 (FY2020 Q3 YTD). The filing was submitted to the U.S. SEC on February 12, 2021. Takeda operates as a global biopharmaceutical company with core therapeutic areas in Gastroenterology (GI), Rare Diseases, Plasma-Derived Therapies (PDT) Immunology, Oncology, and Neuroscience. The company continues to integrate Shire plc and manage divestitures of non-core assets.
Key Financial Metrics
| Metric (Nine-Month Ended Dec 31, 2020) | Value (JPY) | Unit |
|---|---|---|
| Revenue | 2,427,538 | Millions |
| Operating Profit | 358,729 | Millions |
| Net Profit for the Period | 179,027 | Millions |
| Net Profit Attributable to Owners | 178,907 | Millions |
| Basic Earnings Per Share | 114.57 | JPY |
| Net Cash from Operating Activities | 609,971 | Millions |
| Cash and Cash Equivalents (End of Period) | 617,635 | Millions |
| Total Assets | 12,286,137 | Millions |
| Total Liabilities | 7,646,709 | Millions |
| Total Equity | 4,639,428 | Millions |
Underlying Metrics (Non-IFRS): Underlying Revenue Growth was +1.1%. Underlying Core Operating Profit was 780.6 billion JPY with a margin of 32.1%. Underlying Core EPS Growth was +4.5%.
Material Changes vs. Prior Period
- Revenue: Decreased 3.6% (91.9 billion JPY) to 2,427.5 billion JPY. On a constant currency basis, the decline was 1.0%. The decrease was driven by divestitures, generic erosion in Rare Diseases, and foreign exchange headwinds, partially offset by growth in GI, PDT Immunology, and Oncology.
- Profitability: Operating Profit increased 120.7% to 358.7 billion JPY. Net Profit increased 319.0% to 179.0 billion JPY. Significant drivers included a 60.2 billion JPY gain from the release of the obligation to divest the SHP647 pipeline compound and a 37.2 billion JPY gain from the sale of non-core assets.
- Expenses: Cost of Sales decreased 12.0% largely due to a reduction in non-cash charges related to the Shire acquisition inventory step-up. SG&A expenses decreased 9.9% due to cost synergies and reduced travel/event spend from COVID-19. R&D expenses decreased 3.0%.
- Balance Sheet: Total Assets decreased 4.2% to 12.3 trillion JPY, primarily due to amortization of intangible assets and reclassification of goodwill to Assets Held for Sale. Total Liabilities decreased 5.6% to 7.6 trillion JPY, driven by debt repayments and bond redemptions.
Outlook, Risks, and Management Commentary
- COVID-19 Impact: Management states the overall financial impact of COVID-19 was not material, with offsetting factors. Adverse effects in Neuroscience (reduced patient visits) were partially offset by benefits from convenient administration profiles of certain products (e.g., NINLARO). Supply chains remain stable.
- Divestitures: Takeda completed several divestitures of non-core assets in Asia Pacific, Europe, and Canada. The company is also in the process of divesting Takeda Consumer Healthcare Company Limited to Blackstone.
- R&D Pipeline: Key developments include FDA approval for ALUNBRIG (first-line NSCLC), ICLUSIG (CML), and ZEJULA (ovarian cancer) in Japan. The company is advancing CoVIg-19 (hyperimmune globulin) in Phase 3 trials and has partnerships for COVID-19 vaccines (Moderna, Novavax) in Japan.
- Debt Management: Takeda issued $7 billion in USD senior notes and €3.6 billion in Euro senior notes in July 2020 to repay syndicated loans and redeem other bonds early. Subsequent events noted early redemptions of additional USD notes in January 2021.
- Risks: Key risks include the spread of COVID-19, regulatory decisions, competition from generics, and the success of product development programs.
Investor Verification Checklist
- Verify the sustainability of the 120.7% operating profit increase, noting the significant one-time gains (SHP647 release and asset sales) included in Other Operating Income.
- Monitor the progress of the Takeda Consumer Healthcare divestiture to Blackstone and the timing of final closure.
- Assess the impact of foreign exchange rates on future revenue, as the reported decline was 3.6% but only 1.0% on a constant currency basis.
- Review the status of the CoVIg-19 Phase 3 trial and the commercialization timeline for the Moderna and Novavax vaccine partnerships in Japan.
- Track the integration costs and synergy realization from the Shire acquisition, which continues to influence SG&A and restructuring expenses.